Core Viewpoint - RenovoRx, Inc. is advancing its TAMP therapy platform for treating locally advanced pancreatic cancer (LAPC) and will present clinical data at the Symposium on Clinical Interventional Oncology [1][3] Company Overview - RenovoRx is a clinical-stage biopharmaceutical company focused on developing precision oncology therapies using a local drug delivery platform aimed at improving therapeutic outcomes for cancer patients [7] - The company's TAMP (Trans-Arterial Micro-Perfusion) therapy platform is designed to deliver chemotherapy directly to tumors while minimizing systemic side effects [7][8] Clinical Trials and Research - The ongoing Phase III TIGeR-PaC clinical trial is evaluating the TAMP therapy platform in combination with gemcitabine HCl for LAPC patients [4][6] - The first interim analysis of the TIGeR-PaC trial was completed in March 2023, with recommendations to continue the study [6] - The primary endpoint of the trial is a 6-month Overall Survival benefit, with secondary endpoints focusing on reduced side effects compared to standard care [6] Presentation Details - Dr. Ripal Gandhi will present on September 21, 2024, discussing the clinical challenges of standard care for LAPC and the potential of TAMP therapy as a targeted treatment option [5][3] - The presentation will also cover recent publications of clinical data related to the TAMP platform and its application in LAPC [4][3]
RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer